1. Effect of Intravenous Flecainide on Atrial Vulnerability in Man

   • T. Pop II.
   • N. Treese

   Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 1 - 6

2. Clinical Usefulness of Flecainide Acetate in the Treatment of Paroxysmal Supraventricular Arrhythmias

   • A. John. Camm
   • A. Camm
   • Rodney S. Bexton

   Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 7 - 13

3. Comparative Evaluation of Àntiarrhythmic Agents

   • Joel Morganroth

   Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 14 - 20

4. Long Term Use of Flecainide in Patients with Supraventricular Tachycardia

   • H. Neuss

   Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 21 - 25

5. Experience in the Long Term Use of New Antiarrhythmic Drugs

   • T. Meinertz
   • M. K. Zehender
   • T. Pop

   Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 26 - 27

6. The Clinical Use of Oral Flecainide

   • R. Slama
   • J. F. LeClercq

   Section 1: The ‘Benefits’ from the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 28 - 29

7. General Discussion

   • F. Bender

   OriginalPaper 15 December 2012 Pages: 30 - 32

8. Aggravation of Ventricular Arrhythmia

   • Philip J. Podrid

   Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 33 - 44

9. The Proarrhythmic Effects of Flecainide

   • Anthony W. Nathan
   • Kevin J. Hellestrand
   • A. John Camm

   Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 45 - 53

10. Haemodynamic Effects of Class I Antiarrhythmic Agents

    • Victor Legrand
    • Pierre Collignon

    Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 54 - 57

11. Haemodynamic and Antiarrhythmic Effects of Intravenous Flecainide Acetate in Chronic Congestive Heart Failure

    • Peter H. J. M. Dunselman
    • J. Herre Kingma
    • K. I. Lie

    Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 58 - 64

12. Benefit-Risk Ratio in the Treatment of Tachyarrhythmias

    • F. Bender

    Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 65 - 67

13. Logic and Empiricism in the Selection of Antiarrhythmic Agents

    • Philippe Coumel
    • Fabrice Chouty
    • Robert Slama

    Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 68 - 76

14. Antiarrhythmic Therapy with Flecainide in Combination and Comparison with Propranolol

    • H. Stern
    • M. Scheininger
    • K. Theisen

    Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 77 - 85

15. Comparative Evaluation of Antiarrhythmic Therapy

    • L. Kappenberger
    • P. J. Schwartz

    Section 2: The ‘Risks’ Involved with the Clinical Use of Antiarrhythmic Agents 15 December 2012 Pages: 86 - 86

16. General Discussion

    • R. Salma

    OriginalPaper 15 December 2012 Pages: 87 - 88